If the entities other than the cooperative parties need to receive the information of human genetic resources, they need to do information back up and filing.
Suggested Reading
Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation? What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can… How should the evaluation of new items in the endpoint table be considered after the implementation of the new… What factors may affect biocompatibility risk when using biological test data from similar devices for… Do all medical devices require chemical characterization? Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,… For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation… When combining subchronic and implantation tests in one project, what factors need to be considered, and how can… GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which… GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests… Why is the extraction period typically 24 hours in China for cytotoxicity testing? How is the endotoxin limit for wound dressing products determined?